TransTarget

TransTarget is a biotechnology company dedicated to developing transformative therapies for central nervous system (CNS) disorders by overcoming the blood-brain barrier (BBB). Founded by Dr. William M. Pardridge, a pioneer in BBB research, the company utilizes its proprietary Molecular Trojan Horse platform to deliver large-molecule therapeutics into the brain. This technology involves engineering fusion proteins where a therapeutic agent is linked to a monoclonal antibody that targets endogenous BBB transporters, such as the insulin receptor. TransTarget's pipeline focuses on treating lysosomal storage diseases with neurological involvement, as well as neurodegenerative conditions like Alzheimer's disease. By enabling non-invasive delivery of biologics to the brain, the company aims to address significant unmet needs in neurology and oncology.